clinical trial · NCT07036029
NAL ER IPF Respiratory Function and Safety Study
Idiopathic Pulmonary FibrosisNAL ERPlacebo
brief summary
The primary purpose of this study is to assess the safety and tolerability of escalating doses of NAL ER and to evaluate its effect on respiratory function in participants with IPF.
started
Aug 21, 2025
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Apr 9, 2026
official title
An Open Label, In-Clinic Study to Assess Respiratory Function and Safety of Escalating Doses of Nalbuphine Extended-Release Tablets (NAL ER) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol